Table 3 Studies of immune checkpoint inhibitors in ovarian cancer with reported results

Ipilimumab

recurrent EOC, previously treated with GVAX vaccine

I

9

PR (1; 35+ mos.) SD (3; 1 for 6+ mos.)

diarrhea

Hodi et al. [50]

BMS-936559 (anti-PD-L1)

NCT00729664

recurrent EOC

I

17

6% PR (1; 1.3+ mos.) 18% SD (3; 6+ mos.)

infusion-related reaction, adrenal insufficiency

Brahmer et al. [80]

Nivolumab

platinum resistant EOC

II

20

10% CR (2; 11+ mos.) 5% PR (1; 11+ mos.) 30% SD (6; 1 for 11+ mos.)

lymphocytopenia, hypoalbuminemia, elevated ALT, rash, fever, anemia

Hamanishi et al. [25]

Pembrolizumab

NCT02054806

recurrent EOC, PD-L1 positive

Ib

26

4% CR (1; 6+ mos.) 8% PR (2; 6+ mos.) 23% SD (8; 2 for 6+ mos.)

transaminitis

Varga et al. [26]

Ipilimumab

NCT01611558

recurrent EOC

II

40

10% BRR (4; NA)

NA

clinicaltrials.gov [27]

Avelumab

NCT01772004

recurrent EOC

Ib

124

10% PR (12; 4 for 6+ mos.) 44% SD (55; NA)

rash, edema, elevated amylase/lipase, arthritis, colitis, hyperglycemia/DM

Disis et al. [28]

Durvalumab + Olaparib

NCT02484404^a

recurrent EOC

I/II

10

PR (1; 11+ mos.) SD (7; 4+ mos.)

Lymphopenia, anemia

Lee et al. [29]

Durvalumab + Cediranib

4

PR (1; 7 mos.) SD (2; 1 for 6 mos.)

Lymphopenia, anemia, nausea, diarrhea, hypertension, PE, pulmonary hypertension, fatigue, headache